GARDP set up as independent legal entity

[Geneva – 2 April 2019]

GARDP is now an independent legal entity following a successful three-year incubation, hosted by the Drugs for Neglected Diseases initiative (DNDi). During this time, GARDP has already begun working with partners to develop antibiotics to tackle drug-resistant infections which pose a threat to global health and development, including the achievement of the Sustainable Development Goals.

GARDP and Evotec announce new partnership to discover novel antibiotics

[Geneva/Hamburg – 19 March 2019]

GARDP and Evotec AG are announcing the formation of a new strategic public-private partnership to tackle the growing threat of antimicrobial resistance (AMR). By joining forces, Evotec and GARDP will leverage their capabilities and networks to address drug-resistant bacterial infections.

GARDP and Penta partner to accelerate the development of children’s antibiotics to tackle AMR

[Geneva/Padova – 4 March 2019] 

GARDP and Penta, the paediatric infectious diseases research network, have joined forces to tackle drug-resistant infections in children. The strategic collaboration aims to accelerate paediatric development of antibiotic treatments including: clinical trials designed to meet regulatory requirements; and trials with a focus on public health interventions to inform treatment guidelines.

German MOH continues supporting GARDP’s efforts to develop affordable antibiotics

[Geneva – 4 January 2019]
Funding supports developing antibiotics for important global health priorities
GARDP is pleased to receive a EUR 1.5 million investment from the German Federal Ministry of Health (MOH). This funding is already contributing to GARDP’s efforts to develop antibiotics for drug-resistant infections including sexually-transmitted infections and newborns with sepsis – both important global health priorities. The investment also supports GARDP’s growth as its incubation period, hosted by DNDi, comes to an end.